Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Schirmer JH, Aries PM, de Groot K, Hellmich B, Holle JU, Kneitz C, Kötter I, Lamprecht P, Müller-Ladner U, Reinhold-Keller E, Specker C, Zänker M, Moosig F.

Z Rheumatol. 2017 Nov;76(Suppl 3):77-104. doi: 10.1007/s00393-017-0394-1. Review. German. No abstract available.

PMID:
29204681
2.

Immune stimulatory effects of neutrophil extracellular traps in granulomatosis with polyangiitis.

Lange C, Csernok E, Moosig F, Holle JU.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):33-39. Epub 2017 Mar 8.

PMID:
28281454
3.

Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.

Burkel M, Arndt F, Schirmer JH, Moosig F, Holle JU.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):94-97. Epub 2016 Dec 2.

PMID:
27974093
4.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
5.

[Clinical spectrum of IgG4-related diseases and the connection to rheumatology].

Moosig F, Schirmer JH, Lamprecht P, Holle JU.

Z Rheumatol. 2016 Sep;75(7):675-80. doi: 10.1007/s00393-016-0138-7. Review. German.

PMID:
27418057
6.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

7.

Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.

Schirmer JH, Wright MN, Herrmann K, Laudien M, Nölle B, Reinhold-Keller E, Bremer JP, Moosig F, Holle JU.

Arthritis Rheumatol. 2016 Dec;68(12):2953-2963. doi: 10.1002/art.39786.

8.

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Schirmer JH, Bremer JP, Moosig F, Holle JU, Lamprecht P, Wieczorek S, Haenisch S, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):367-74. doi: 10.2217/pgs.15.176. Epub 2016 Feb 19.

PMID:
26894931
9.

Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Herrmann K, Schinke S, Csernok E, Moosig F, Holle JU.

Open Rheumatol J. 2015 Oct 9;9:71-6. doi: 10.2174/1874312901409010071. eCollection 2015.

10.

Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.

Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, Henes FO, Arlt A, Gross WL, Schinke S, Reinhold-Keller E, Moosig F, Holle JU.

Rheumatology (Oxford). 2016 Jan;55(1):71-9. doi: 10.1093/rheumatology/kev286. Epub 2015 Aug 20.

PMID:
26297628
11.

Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.

Schirmer JH, Thorns C, Moosig F, Holle JU.

Rheumatology (Oxford). 2015 Oct;54(10):1932-4. doi: 10.1093/rheumatology/kev237. Epub 2015 Jul 2. No abstract available.

PMID:
26139656
12.

[ANCA-associated vasculitis].

Holle JU.

Internist (Berl). 2015 Jan;56(1):41-50; quiz 51-2. doi: 10.1007/s00108-014-3613-8. German.

PMID:
25502657
13.

Of evidence and uncertainties.

Moosig F, Holle JU.

Rheumatology (Oxford). 2014 Dec;53(12):2129-30. doi: 10.1093/rheumatology/keu009. Epub 2014 Mar 4. No abstract available.

PMID:
24599910
14.

The SEM6A6 locus is not associated with granulomatosis with polyangiitis or other forms of antineutrophil cytoplasmic antibody-associated vasculitides in Europeans: comment on the article by Xie et al.

Wieczorek S, Holle JU, Cohen Tervaert JW, Harper L, Moosig F, Gross WL, Epplen JT.

Arthritis Rheumatol. 2014 May;66(5):1400-1. doi: 10.1002/art.38367. No abstract available.

15.

[Genetic risk factors for vasculitis].

Holle JU, Gross WL.

Internist (Berl). 2014 Feb;55(2):128-34. doi: 10.1007/s00108-013-3305-9. German.

PMID:
24217527
16.

Caveolin-1 single nucleotide polymorphism in antineutrophil cytoplasmic antibody associated vasculitis.

Chand S, Holle JU, Hilhorst M, Simmonds MJ, Smith S, Kamesh L, Hewins P, McKnight AJ, Maxwell AP, Cohen Tervaert JW, Wieczorek S, Harper L, Borrows R.

PLoS One. 2013 Jul 19;8(7):e69022. doi: 10.1371/journal.pone.0069022. Print 2013.

17.

[ANCA-associated vasculitis].

Holle JU.

Z Rheumatol. 2013 Jun;72(5):445-56. doi: 10.1007/s00393-013-1211-0. German.

PMID:
23743987
18.

Genetics of toll like receptor 9 in ANCA associated vasculitides.

Husmann CA, Holle JU, Moosig F, Mueller S, Wilde B, Cohen Tervaert JW, Harper L, Assmann G, Gross WL, Epplen JT, Wieczorek S.

Ann Rheum Dis. 2014 May;73(5):890-6. doi: 10.1136/annrheumdis-2012-202803. Epub 2013 Apr 16.

PMID:
23592712
19.

L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: different outcomes?

Holle JU.

Presse Med. 2013 Apr;42(4 Pt 2):616-9. doi: 10.1016/j.lpm.2013.01.041. Epub 2013 Mar 6. No abstract available.

PMID:
23481358
20.

Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis.

Holle JU, Windmöller M, Lange C, Gross WL, Herlyn K, Csernok E.

Rheumatology (Oxford). 2013 Jul;52(7):1183-9. doi: 10.1093/rheumatology/kes415. Epub 2013 Feb 12.

PMID:
23407387
21.

Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage.

Holle JU, Voigt C, Both M, Holl-Ulrich K, Nölle B, Laudien M, Moosig F, Gross WL.

Rheumatology (Oxford). 2013 May;52(5):875-82. doi: 10.1093/rheumatology/kes382. Epub 2013 Jan 4.

PMID:
23293138
22.

[First genomewide association study of ANCA-associated vasculitis].

Holle JU.

Z Rheumatol. 2013 Mar;72(2):187-8. doi: 10.1007/s00393-012-1087-4. German. No abstract available.

PMID:
23247869
23.

[How I treat …].

Moosig F, Reinhold-Keller E, Holl-Ulrich K, Feller AC, Bley T, Holle JU, Zwerina J, Lamprecht P, Dalhoff K, Venhoff N, Thiel J, Peter HH, Laudien M, Quetz J, Ambrosch P, Both M, Heller M.

Z Rheumatol. 2012 Nov;71(9):775-84. doi: 10.1007/s00393-012-0988-6. German. No abstract available.

PMID:
23138555
24.

[Update on granulomatosis with polyangitis (GPA, Wegener's granulomatosis)].

Holle JU, Reinhold-Keller E, Gross WL.

Z Rheumatol. 2012 Nov;71(9):745-53. doi: 10.1007/s00393-012-0982-z. German.

PMID:
23138551
25.

[Neurological manifestations of vasculitis and primary central nervous system vasculitis].

Magnus T, Melms A, Kötter I, Holle JU.

Z Rheumatol. 2012 Sep;71(7):551-63. doi: 10.1007/s00393-012-0957-0. German.

PMID:
22930106
26.

Treatment of ANCA-associated vasculitides (AAV).

Holle JU, Gross WL.

Autoimmun Rev. 2013 Feb;12(4):483-6. doi: 10.1016/j.autrev.2012.08.007. Epub 2012 Aug 16. Review.

PMID:
22921792
27.

A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.

Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, Matthis C, Metzler C, Nölle B, Richardt G, Gross WL.

Ann Rheum Dis. 2013 Jun;72(6):1011-7. doi: 10.1136/annrheumdis-2012-201531. Epub 2012 Aug 11.

PMID:
22887848
28.

Genetically distinct subsets within ANCA-associated vasculitis.

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG.

N Engl J Med. 2012 Jul 19;367(3):214-23. doi: 10.1056/NEJMoa1108735.

29.

Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides.

Holle JU, Herrmann K, Gross WL, Csernok E.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S66-9. Epub 2012 May 10.

PMID:
22512915
30.

[Primary systemic vasculitides].

Schinke S, Herlyn K, Holle JU, Gross WL.

Dtsch Med Wochenschr. 2012 Feb;137(8):373-84; quiz 385-6. doi: 10.1055/s-0031-1292876. Epub 2012 Feb 14. Review. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2012 Mar;137(11):515.

PMID:
22334364
31.

Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.

Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, Reinhold-Keller E, Gross WL.

Ann Rheum Dis. 2012 Mar;71(3):327-33. doi: 10.1136/ard.2011.153601. Epub 2011 Oct 21.

PMID:
22021864
32.

Rituximab in AAV: when and how to use it.

Holle JU, Gross WL.

Nat Rev Rheumatol. 2011 Aug 30;7(10):566-7. doi: 10.1038/nrrheum.2011.131. No abstract available.

PMID:
21878889
33.

ANCA-associated vasculitis is linked to carriage of the Z allele of α₁ antitrypsin and its polymers.

Morris H, Morgan MD, Wood AM, Smith SW, Ekeowa UI, Herrmann K, Holle JU, Guillevin L, Lomas DA, Perez J, Pusey CD, Salama AD, Stockley R, Wieczorek S, McKnight AJ, Maxwell AP, Miranda E, Williams J, Savage CO, Harper L.

Ann Rheum Dis. 2011 Oct;70(10):1851-6. doi: 10.1136/ard.2011.153569. Epub 2011 Aug 5.

PMID:
21821620
34.

Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides.

Holle JU, Moosig F, Dalhoff K, Gross WL.

Arthritis Res Ther. 2011 Jun 30;13(3):224. doi: 10.1186/ar3307. Review.

35.

[Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)].

Holle JU, Moosig F, Gross WL; European League Against Rheumatism (EULAR); European Vasculitis Study Group (EUVAS).

Internist (Berl). 2011 Jun;52(6):671-81. doi: 10.1007/s00108-010-2772-5. German.

PMID:
21512793
36.

[The genetics of vasculitides].

Holle JU, Wieczorek S, Epplen JT, Gross WL.

Z Rheumatol. 2011 Apr;70(3):198, 200-4. doi: 10.1007/s00393-010-0692-3. German.

PMID:
21264471
37.

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

Fröhlich K, Holle JU, Aries PM, Gross WL, Moosig F.

Ann Rheum Dis. 2011 Jul;70(7):1344-5. doi: 10.1136/ard.2010.133256. Epub 2010 Dec 20. No abstract available.

PMID:
21173019
38.

Neurological involvement in Wegener's granulomatosis.

Holle JU, Gross WL.

Curr Opin Rheumatol. 2011 Jan;23(1):7-11. doi: 10.1097/BOR.0b013e32834115f9. Review.

PMID:
21124081
39.

Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades.

Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E.

Arthritis Rheum. 2011 Jan;63(1):257-66. doi: 10.1002/art.27763.

40.

[Classification and therapy of vasculitis according to recommendations of the European League Against Rheumatism (EULAR)].

Holle JU, Bley T, Gross WL.

Radiologe. 2010 Oct;50(10):846-54. doi: 10.1007/s00117-010-2000-2. German.

PMID:
20717646
41.

Are there specific genetic risk factors for the different forms of ANCA-associated vasculitis?

Arning L, Holle JU, Harper L, Millar DS, Gross WL, Epplen JT, Wieczorek S.

Ann Rheum Dis. 2011 Apr;70(4):707-8. doi: 10.1136/ard.2010.130971. Epub 2010 Aug 10. No abstract available.

PMID:
20699237
42.

The future of ANCA-associated vasculitis.

Holle JU, Wieczorek S, Gross WL.

Rheum Dis Clin North Am. 2010 Aug;36(3):609-21. doi: 10.1016/j.rdc.2010.05.007.

PMID:
20688253
43.

Clinical manifestations and treatment of Wegener's granulomatosis.

Holle JU, Laudien M, Gross WL.

Rheum Dis Clin North Am. 2010 Aug;36(3):507-26. doi: 10.1016/j.rdc.2010.05.008.

PMID:
20688247
44.

Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis.

Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F.

Ann Rheum Dis. 2010 Oct;69(10):1888-9. doi: 10.1136/ard.2009.119172. Epub 2010 Jun 11. No abstract available.

PMID:
20542962
45.

The role of proteinase 3 (PR3) and the protease-activated receptor-2 (PAR-2) pathway in dendritic cell (DC) maturation of human-DC-like monocytes and murine DC.

Jiang B, Grage-Griebenow E, Csernok E, Butherus K, Ehlers S, Gross WL, Holle JU.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):56-61.

PMID:
20412704
46.

Membrane proteinase 3 (mPR3) expression on neutrophils is not increased in localized Wegener's granulomatosis (WG) and Churg-Strauss syndrome (CSS).

Holle JU, Wu QJ, Moosig F, Gross WL, Csernok E.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):46-50.

PMID:
20412702
47.

Genetic association studies in ANCA-associated vasculitides: what we have learnt so far and what needs to be done in the future.

Holle JU, Wieczorek S, Gross WL.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):5-7. No abstract available.

PMID:
20412694
48.

Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?

Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, Csernok E, Moosig F, Schinke S, Reinhold-Keller E.

Ann Rheum Dis. 2010 Nov;69(11):1934-9. doi: 10.1136/ard.2010.130203. Epub 2010 May 28.

PMID:
20511614
49.

Diagnostic and therapeutic management of Churg-Strauss syndrome.

Holle JU, Moosig F, Gross WL.

Expert Rev Clin Immunol. 2009 Nov;5(6):813-23. doi: 10.1586/eci.09.41.

PMID:
20477699
50.

Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology?

Csernok E, Holle JU.

Auto Immun Highlights. 2010 Jul 10;1(1):39-43. doi: 10.1007/s13317-010-0007-3. eCollection 2010 May. Review.

Supplemental Content

Loading ...
Support Center